In a significant development, statutory health insurance providers in Germany will now be able to cover the costs for several medications used to treat Long Covid. This is noteworthy because these drugs are not officially approved for this specific condition, a practice known as ‘off-label’ use. The decision by the Federal Joint Committee (G-BA) to allow reimbursement for four such medications marks a crucial step for patients seeking relief. This article will further explore the implications of this ruling and present what medical experts and healthcare professionals think about this new policy.
